RANCHO CORDOVA, Calif. and KING OF PRUSSIA, Pa., Oct. 18, 2023 /PRNewswire/ — SK pharmteco will participate in CPHI 2023 in Barcelona and will prepare an exclusive exhibitor at the event. As a multimodal CDMO with expertise in small molecule active pharmaceutical ingredients (APIs) and biopharmaceuticals, SK pharmteco aims to present its business competitiveness and actively pursue business opportunities.
CPHI, scheduled for October 24-26 in Barcelona, ??Spain, is the leading trade fair for the pharmaceutical and chemical industry. Featuring over 2,000 pharmaceutical suppliers and attracting over 40,000 industry stakeholders, the event offers an unrivaled platform to network and forge partnerships.
Visitors are welcomed to booth 3K70, the contract manufacturing and services area, to see the company’s latest innovations. Previously, the SK pharmteco display was located in the API section. The company has changed its location this year to enhance its position as a leading multimodal CDMO in lieu of the company’s evolving business portfolio that spans from small molecule APIs to cell and gene therapies.
The event will be attended by key executives including Joerg Ahlgrimm, CEO of SK pharmteco, along with representatives from its subsidiaries including AMPAC Fine Chemicals, SK biotek Ireland, Yposkesi and Center for Breakthrough Medicines (CBM). CBM is a US cell and gene therapy CDMO in which SK pharmteco recently acquired a majority stake.
SK pharmteco has recently established the role of chief commercial officer (CCO) as part of its strategic initiative to enhance its marketing and customer-centric strategies. The company appointed Andrew Fenny, former chief commercial officer of FUJIFILM Diosynth Biotechnologies (FDB), a global CDMO, to assume CCO responsibilities. In his new role, Fenny will lead global customer engagement functions with the goal of delivering customized solutions for SK pharmteco partners.
At CPHI, SK pharmteco aims to leverage various networking events to showcase its key strengths. These include introducing its extensive global supply chain that spans the United States, Europe and Asia. Additionally, the company will showcase its comprehensive end-to-end services for cell and gene therapies, along with its unparalleled continuous flow process manufacturing technology for small molecule APIs.
SK pharmteco’s modular platform for rapid and flexible continuous manufacturing of APIs earned recognition as a finalist in the Innovation Acceleration category at this year’s CPHI Pharma Awards. These awards commend the exceptional contributions made by companies and individuals to the progress of the pharmaceutical industry over the past year. The finalists were chosen by a panel of experts representing pharmaceutical companies, consultancies and academia worldwide.
Continuous manufacturing technology uses automation to produce products seamlessly and in an uninterrupted flow at every step of the process. It has proven to be more cost-effective, productive and ensures higher quality and safety compared to conventional processes, leading to a significant reduction in overall waste production. The final winners will be announced at the awards ceremony on October 24, the opening day of CPHI Barcelona.
“With the recent acquisition of a majority stake in CBM, SK pharmteco is advancing its biobusiness by establishing large-scale production facilities for cell and gene therapies in the United States and Europe,” said Joerg Ahlgrimm, CEO of SK pharmteco. . “Our commitment is unwavering in creating diverse opportunities for sustained growth, positioning us as a leading company with world-class global competitiveness across the spectrum, from small molecule APIs to biopharmaceuticals.”
SK pharmteco is a subsidiary of SK Inc. (KRX: 034730) (SK), the strategic investment company of SK Group, South Korea’s second largest conglomerate, and has 13 offices and manufacturing facilities in the United States, Europe and Korea, all with a combined vision of providing life-changing and life-saving therapies to more than 200 million patients by 2026.
For more information about SK pharmteco, visit skpharmteco.com
Photo – https://mma.prnewswire.com/media/2249411…
View original content: https://www.prnewswire.com/news-releases/sk-pharmteco-exhibira-sus-amplias-capacidades-de-api-y-cgt-en-cphi-2023-301960927.html
